Fruquintinib Phase III Start Marks More China Innovation
This article was originally published in PharmAsia News
Executive Summary
Hutchison MediPharma (HMP) has initiated a pivotal Phase III trial program in China with its most advanced pipeline oncology project, fruquintinib.